Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty
Christopher Wanderling(University of Rochester), Jawed Fareed(Loyola University Chicago), Elissa Finkler(Loyola University Medical Center), Nil Güler(Loyola University Medical Center), William Hopkinson(Loyola University Medical Center), Debra Hoppensteadt(Brigham and Women's Hospital), Peter Carlsgaard(Loyola University Chicago), Jeffrey Liles(Loyola University Chicago)
Cited by 19
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy
|JAMA|2019|370
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*
|Critical Care Medicine|2013|322
Nailfold Capillary Abnormalities in Primary Open-Angle Glaucoma: A Multisite Study
|Investigative Ophthalmology & Visual Science|2015|38
Recent Advances in Surgical Simulation For Resident Education
|Current Urology Reports|2023|30